Business
PharmaResearch Establishes European Distribution Partnership for 'Rejuran'
PharmaResearch (CEO: Jihoon Sohn), a leading regenerative medicine company, announced today the signing of a strategic partnership agreement with VIVACY, a France-based global medical aesthetics company, to distribute its medical device brand Rejuran in the European market.
About this update from Pharmaresearch Co., Ltd.
[{"type":"text","content":"Secures Strategic Distribution Network Across 22 European Countries, Including Key Markets Such as the UK, Germany, and France","length":126,"tagName":"p"},{"type":"text","content":"SEONGNAM, South Korea, Aug. 28, 2025 /PRNewswire/ -- PharmaResearch (CEO: Jihoon Sohn), a leading regenerative medicine company, announced today the signing of a strategic partnership agreement with VIVACY, a France-based global medical aesthetics company, to distribute its medical device brand Rejuran in the European market.","length":332,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/PharmaResearch)","displaySize":"","headline":null,"caption":"(PRNewsfoto/PharmaResearch)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":104,"url":"https://media.zenfs.com/en/prnewswire.com/9d295cf84a1ba3def3a878e92749c2c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rrKdtV0hIXsOjyxhhZlBNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9d295cf84a1ba3def3a878e92749c2c8","width":400,"height":104}},"href":"https://mma.prnewswire.com/media/2710342/CI_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"VIVACY, headquartered in France, is one of the leading company's in the European medical aesthetics industry. With subsidiaries and branch offices across key cities in Europe, VIVACY has built a robust commercial and marketing network.","length":239,"tagName":"p"},{"type":"text","content":"Through this strategic partnership, PharmaResearch aims to combine VIVACY's vast distribution network along with their expertise in the market to accelerate their brand's entry and presence in Europe.","length":208,"tagName":"p"},{"type":"text","content":"The agreement is valued at approximately EUR 54.5 million over 5 years and spans to 22 countries, including the major Western European markets (United Kingdom, Germany, France, Italy, and Spain).","length":195,"tagName":"p"},{"type":"text","content":"PharmaResearch plans to start distributing in the key European countries within this year, followed by a phased rollout across the region.","length":138,"tagName":"p"},{"type":"text","content":"Jihoon Sohn, CEO of PharmaResearch, commented that, "Rejuran is currently the only PN (Polynucleotide)-based medical device approved under the EU Medical Device Reg...